Press Releases
ITI Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at AACR 2022
Featured Highlights Press Press ReleasesBoth DNA Cancer Vaccines Studied Were Derived from Immunomic’s UNITE™ Platform Phase 1 Study of MCPyV-LT Vaccine in Merkel Cell Carcinoma to Begin in Q2 April 08, 2022 01:15 PM EasternRead moreITI Announces Two Poster Presentations at AACR Annual Meeting 2022
Featured Highlights Press Press ReleasesMarch 31, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today thatRead moreITI to present at the BIO CEO & Investor Conference 2022
Featured Highlights Press Press ReleasesFebruary 11, 2022 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced todayRead moreITI Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma
Featured Highlights Press Press ReleasesFebruary 07, 2022 01:48 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleicRead moreImmunomic Therapeutics’ CBO to present at the 14th Annual Biotech Showcase Event
Featured Highlights Press ReleasesJanuary 06, 2022 12:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced todayRead more- Featured Highlights Press Press ReleasesNovember 30, 2021 02:01 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced the openingRead more
Immunomic Therapeutics Announces Collaboration With iOncologi
Featured Highlights Press Press Releases- Potential to bring in-house cell-based therapies that potentiate checkpoint inhibitors November 23, 2021 06:41 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnologyRead more- Featured Highlights Press Press ReleasesNovember 18, 2021 ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (‘ITI’), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that Kristen Batich, MD, Ph.D.Read more
Immunomic Therapeutics Expands Board of Directors with Appointments of Two New Members
Featured Highlights Press Press ReleasesJuly 27, 2021 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced todayRead moreITI’s Academic Collaborator Dr. John Sampson Recognized as “World Expert” in Glioblastoma
Featured Highlights Press Press ReleasesJuly 21, 2021 10:35 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced todayRead moreITI Strengthens Leadership Team with Appointment of Robert Newman as Chief Business Officer
Featured Highlights Press Press ReleasesBiotech leader joins team as company evolves investigational UNITE platform and advances business July 19, 2021 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinicalRead moreImmunomic Therapeutics to Participate at World Vaccine Congress Washington 2021
Featured Highlights Press Press ReleasesApril 27, 2021 12:00 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually May 4-6, 2021.Read more